- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Tahir Amin: Bringing Down the Cost of Drugs
Tahir Amin, DipLP, co-founder and director of intellectual property of Initiative for Medicines, Access, and Knowledge, discusses how his organization has helped bring down drug costs.
Transcript:
How has your work affected access to and the cost of HIV therapies?
I think we’ve seen the cost come down significantly, and a lot of that is because of the advocacy, the patient community, and global health organizations putting this issue on the agenda.
I do believe the newer generations of drugs are still farther out of reach, particularly for middle-income countries. For example, a number of least-developing countries are getting included in access programs or licenses, so those countries are getting some of the benefits of the work that’s being done; however, a number of middle-income countries are being left out since they’re emerging markets.
So, those countries are facing a big crisis in terms of accessing these drugs at affordable prices. I think that’s where a lot of the work has to be concentrated now, because there’s been a tradeoff where pharmaceutical companies have said, “Well, we’ll give to the least-developing countries but keep the bigger markets to ourselves.” So, the prices are still around $5000 to $7000, and there’s more poor people living in middle-income countries than almost anywhere else. That’s where the crisis really lies and if we don’t solve that problem than we’re going to be facing another HIV crisis, as we did in the early days.
PBM Evolution Toward Value-Based Care Shifts to Transparent Pharmacy Pricing
March 30th 2025Josh Canavan, PharmD, RazorMetrics, and Chris O'Dell, Turquoise Health, predict pharmacy benefit managers (PBMs) will evolve toward value-based care, mirroring the broader shift toward open-cost structures.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Empowering Vulnerable Populations: The Path to Equitable Biologic Therapy Access
December 22nd 2024Elie Bahou, PharmD, senior vice president and system chief pharmacy officer at Providence, discusses strategies to improve equitable access to biologic therapies, including tiered formularies, income-based cost sharing, patient assistance programs, and fostering payer partnerships.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Can Global Policies to Boost Biosimilar Adoption Work in the US?
November 17th 2024On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the Biosimilars Council, explores how global policies—from incentives to health equity strategies—could boost biosimilar adoption in the US.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
